TOI Clinical Research

Cerritos, California 90703-2684

2 studies enrolling now · 12 studies all time

What they study most

Advanced Solid Tumors, Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Chronic Lymphocytic Leukemia, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer, Follicular Lymphoma, HER2-Positive Advanced Biliary Tract Cancer, HER2-positive Breast Cancer, Hematologic Malignancies, Leukemia, B-cell, Leukemia, Lymphocytic, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer

Studies at this site

• A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer — Recruiting now
• A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — Recruiting now
• Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment — Recruiting now
• XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer — Completed
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) — Running, not enrolling
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC — Stopped early
• A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors — Running, not enrolling
• A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer — Running, not enrolling
• A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease — Completed
• An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer — NO_LONGER_AVAILABLE
• Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients — Stopped early